酮替芬联合盐酸氨溴索雾化治疗对小儿支气管炎呼吸功能指标的影响

The effect of ketotifen combined with ambroxol hydrochloride atomization treatment on respiratory function index of children with bronchitis

目的探究分析酮替芬联合盐酸氨溴索雾化治疗对小儿支气管炎呼吸功能指标的影响。方法选取2014年10月至2016年10月期间来本院就诊的支气管炎症患儿58例为研究对象，采用随机数字表法将所有患儿分为试验组和对照组，两组各29例。所有患儿均给予常规对症治疗。对照组在常规治疗基础上加用酮替芬口服治疗，试验组在常规治疗基础上加用酮替芬联合盐酸氨溴索雾化吸入治疗，两组患儿治疗前后呼吸功能改善情况、临床症状缓解情况以及药物不良反应情况比较。结果两组患儿潮气量、呼吸频率（RR）、达峰时间比（tPTEF，tE）和达峰容积比（VPTEF／VE）等呼吸功能指标水平均较治疗前明显好转，且治疗后试验组患儿潮气量、tPTEF／tE、VPTEF／VE[（7．54土1．24）mUkg、（28．68±4．51）%、（30．42±5．31）％]明显高于同期对照组患儿[（6．31±1．21）ml／kg、（24．12±3．72）％、（25．64±3．75）％]，差异有统计学意义（P〈0．05），其RR[（30．11±5．23）次／min]则明显低于对照组[（37．44±5．15）次，min]水平，差异有统计学意义（P〈0．05）。经不同药物干预治疗后，试验组患儿咳嗽、气促、湿哕音、哮鸣音等临床症状消失时间及心率、体温恢复时间[（5．13±1．10）d、（4．12±0．74）d、（5．20±1．04）d、（3．24±0．47）d、（2．14±0．64）d、（2．43±0．53）d]均明显较对照组患儿[（6．76±1．53）d、（6．45±1．33）d、（7．32±1．41）d、（5．11±0．84）d、（3．52±1．10）d、（4．85±0．66）d1偏短．差异有统计学意义（P〈0．05）。试验组患儿出现皮疹、荨麻疹、喉部刺激不适、声嘶及咳嗽等药物不良反应几率为13．79％，明显低于对照组水平37．93％，差异有统计学意义（P〈0．05）。结论酮替芬配合盐酸氨溴索化吸入治疗能明显改善支气管炎症患儿的临床症状，缩短临床治疗时间，促进呼吸功能恢复，疗效显著，安全性高。

Objective To explore the effect of ketotifen combined with ambroxol hydrochloride atomization treatment on respiratory function index of children with bronchitis. Methods 58 children with bronchitis in our hospital from October 2014 to October 2016 were selected as clinical research object, and divided into test group and control group according to the random number table method, 29 cases in each group. All children were given conventional treatment, on the basis the children of control group were given oral ketotifen, the children of test group were given ketotifen combined with ambroxol hydrochloride atomization treatment. Compared respiratory function, clinical symptoms before and after treatment, and adverse drug reactions of two groups. Resalts The levels of tidal volume, resp/ratory rate （RR）, tPTEF/tE, and VPTEF/VE improved markedly in the two groups after treatment, the levels of tidal volume, tPTEF/tE, and VPTEF/VE of the test group were significantly higher than those of the control group [（7.54± 1.24）ml/kg vs.（6.31± 1.21）ml/kg, （28.68±4.51）% vs.（24.12±3.72）%, （30.42±5.31）% vs.（25.64±3.75）%; P〈0.05], RR was significantly lower than that oftbe control group [（30.11±5.23） times/rain vs.（37.44±5.15） times/min; P〈0.05]. The clinical symptoms disappear time （cough, shortness of breath, wet rale, and wheeze） and the recovery time of heart rate and body temperature of：the test group were significantly shorter than those of the control group [（5.13±1.10）d vs.（6.76±1.53）d, （4.12±0.74） d vs.（6.45±1.33）d, （5.20±1.04）d vs.（7.32±1.41）d, （3.24±0.47）d vs.（5.11±0.84）d, （2.14±0.64）d vs.（3.52±1.10）d, （2.43±0.53）d vs.（4.85±：0.66）d; P〈0.05]. The incidence of adverse drug reactions （rash, urticaria, throat stimulation and discomfort, hoarseness, and cough） of the test group was significantly lower than that of the control group （13.79% vs.37.93%; P〈0.05）. Conclusion Ketotifen combined with ambroxol hydrochloride atomization treatment can obviously improve the clinical symptoms of children with bronchitis, shorten the treatment time, promote the recovery of respiratory function, with distinct curative effect and high safety.